BlossomHill Therapeutics is a technology company.
BlossomHill Therapeutics has raised $171.0M across 2 funding rounds.
BlossomHill Therapeutics has raised $171.0M in total across 2 funding rounds.
BlossomHill Therapeutics has raised $171.0M in total across 2 funding rounds.
BlossomHill Therapeutics's investors include General Catalyst, OrbiMed, Sofinnova Investments.
BlossomHill Therapeutics is a clinical-stage biopharmaceutical company designing and developing next-generation small-molecule therapies for cancer and autoimmune diseases.[1][2] Founded by J. Jean Cui, Ph.D., the company focuses on precision medicines that target oncogenic drivers and resistance mechanisms, with lead programs including BH-30643 (a first-in-class macrocyclic OMNI-EGFR inhibitor for EGFR/HER2-mutated NSCLC) and BH-30236 (a macrocyclic CLK inhibitor for R/R AML or HR-MDS).[2][4] It serves patients with difficult-to-treat cancers and autoimmune conditions, addressing unmet needs like treatment resistance through intelligently designed drugs built from the ground up.[1][2] The company has raised $257 million total, including an $84 million Series B extension in 2025 led by Janus Henderson Investors, accelerating its pipeline.[2]
BlossomHill Therapeutics was founded in 2020 in San Diego, California, by J. Jean Cui, Ph.D., a prolific drug designer with a track record of three FDA-approved cancer drugs: repotrectinib (AUGTYRO®), crizotinib (XALKORI®), and lorlatinib (LORBRENA®).[1][2][3] Cui, inspired by the need to transcend incremental advances in precision medicine, combined her scientific expertise with creative thinking to build novel therapeutic candidates.[1] Y. Peter Li serves as co-founder, with prior collaboration on Turning Point Therapeutics, which Cui and Li founded and Bristol Myers Squibb acquired in 2022.[1][3] Early momentum came from assembling a world-class pipeline and securing funding from top investors like OrbiMed and Vivo Capital.[2]
BlossomHill rides the wave of precision oncology and targeted therapies, capitalizing on advances in mutant-selective inhibitors amid rising NSCLC and AML incidences.[2][4] Timing aligns with post-2022 oncology M&A trends, building on Cui's Turning Point success acquired by Bristol Myers Squibb, amid a biotech funding rebound in 2025.[1][2] Market forces like demand for resistance-breaking drugs favor its macrocyclic designs, addressing limitations in existing EGFR/CLK therapies.[1][2] It influences the ecosystem by validating small-molecule innovation from serial entrepreneurs, attracting capital to San Diego's biotech hub and advancing clinical trials for hard-to-treat cancers.[4]
BlossomHill is poised for milestone readouts from BH-30643 and BH-30236 trials, potentially driving partnerships or acquisition interest given its $257M war chest and founder's pedigree.[2][4] Trends like AI-augmented drug design and immuno-oncology combos will shape its path, expanding its autoimmune programs amid a push for multi-modal therapies.[1] Influence may grow through FDA nods or buyouts, solidifying its role in leapfrogging precision medicine—echoing its mission to create medical masterpieces that extend patient lifespans.[1]
BlossomHill Therapeutics has raised $171.0M across 2 funding rounds. Most recently, it raised $100.0M Series B in January 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2024 | $100.0M Series B | General Catalyst, OrbiMed, Sofinnova Investments | |
| Mar 1, 2021 | $71.0M Series A | General Catalyst, OrbiMed, Sofinnova Investments |